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Abstract
Background: Bipolar disorder is a severe psychiatric disorder with high heritability. Co-morbid conditions are common and
might define latent subgroups of patients that are more homogeneous with respect to genetic risk factors.
Methodology: In the Caucasian GAIN bipolar disorder sample of 1000 cases and 1034 controls, we tested the association of
single nucleotide polymorphisms with patient subgroups defined by co-morbidity.
Results: Bipolar disorder with psychosis and/or substance abuse in the absence of alcohol dependence was associated with
the rare variant rs1039002 in the vicinity of the gene phosphodiesterase 10A (PDE10A) on chromosome 6q27 (p=1.7610
28).
PDE10A has been implicated in the pathophysiology of psychosis. Antagonists to the encoded protein are currently in
clinical testing. Another rare variant, rs12563333 (p=5.9610
28) on chromosome 1q41 close to the MAP/microtubule
affinity-regulating kinase 1 (MARK1) gene, approached the genome-wide level of significance in this subgroup.
Homozygotes for the minor allele were present in cases and absent in controls. Bipolar disorder with alcohol dependence
and other co-morbidities was associated with SNP rs2727943 (p=3.3610
28) on chromosome 3p26.3 located between the
genes contactin-4 precursor (BIG-2) and contactin 6 (CNTN6). All three associations were found under the recessive genetic
model. Bipolar disorder with low probability of co-morbid conditions did not show significant associations.
Conclusion: Conceptualizing bipolar disorder as a heterogeneous disorder with regard to co-morbid conditions might
facilitate the identification of genetic risk alleles. Rare variants might contribute to the susceptibility to bipolar disorder.
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Introduction
Bipolar disorder (BPD) is a mental disorder with dramatic and
unpredictable mood swings between mania and depression. It
affects approximately 5.7 million American adults or 2.6 percent
of the U.S. population aged 18 and older in a given year (http://
www.nimh.nih.gov/health/publications/the-numbers-count-men-
tal-disorders-in-america/index.shtml). The symptoms of BPD vary
considerably. Therefore, this disorder has also been conceptual-
ized as a group of related mood disorders referred to as bipolar
spectrum disorders. It remains unclear if these conditions share a
common pathophysiology or common risk factors. Recently, co-
morbid conditions in BPD have drawn attention as potential
indicators of pathologically distinct subtypes [1].
Co-morbid conditions are common in BPD. They are often
related to the severity of the disorder and may aggregate in
families. Familial aggregation has been shown for co-morbid
attention deficit hyperactivity disorder (ADHD) [2], alcohol use
disorders, and panic disorder [3], as well as psychosis [4]. Familial
aggregation of co-morbid conditions can be caused by shared
environment, shared genetic risk factors or a combination of
both. Therefore, co-occurrence in families alone cannot clearly
differentiate between these possible causes. Twin studies compar-
ing the occurrence rate in monozygotic twins versus dizygotic
twins revealed that the susceptibility to BPD, substance abuse, as
well as alcohol dependence could be influenced by genetic factors
[5–9]. Shared pathophysiology might explain the common and
characteristic co-occurrence of these disorders [10,11]. Exposure
to substances of abuse at certain vulnerable times during
development might in itself increase risk for psychotic disorders
in individuals with certain genetic susceptibilities [12,13]. The
identification of genetic risk alleles associated with BPD, substance
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complex and interrelated factors.
The search for genetic risk factors in BPD has recently drawn
attention to some genomic variants that might play a role in BPD.
In genome-wide association studies, several common variants have
been found to be significantly associated with BPD. Among those
are the single nucleotide polymorphism (SNP) rs1012053 in
the first intron of the gene diacylglycerol kinase eta (DGKH)
(HGNC:2854) on chromosome 13q14.1 [14], variants in the gene
voltage-dependent L-type calcium channel subunit alpha-1C
(CACNA1C) (HGNC:1390) on chromosome 12p13 [15] and the
intronic SNP rs10994336 in the Ankyrin-3 (ANK3) (HGNC:494)
gene on chromosome 10q21 [16,17]. In addition, rare structural
variants as well as common variants in gene deserts have been
suggested. However, replication of these findings has been
challenging. A previous analysis of the data set used in our
analysis failed to report genome-wide significant associations [18].
BPD is likely to be a heterogeneous disorder. Samples consisting
of unidentified subgroups that behave differently with regard to
the problem at hand introduce noise to the data and might lead to
increased type 1 and type 2 errors [19]. In order to explore
phenotype heterogeneity in the Genetic Association Information
Network (GAIN) Bipolar Disorder sample, we used a multivariate
latent class analysis (LCA) to define subgroups of BPD patients
based on profiles of psychiatric co-morbid conditions. Using this
approach, BPD patients could be assigned to their most likely
latent class. We then tested the relationship of SNPs from a
genome-wide scan genotyped on the Affymetrix 6.0 array for
association with the latent classes. Our approach identified several
highly significant associations with rare, as well as common,
genomic variants.
Subgroups of patients defined by co-morbid conditions might be
more homogeneous with respect to underlying genetic risk factors.
Therefore, sub-grouping of BPD patients according to co-morbid
conditions might identify additional genomic variants that are
associated with a particular sub-phenotype.
Materials and Methods
Ethics statement
All participants gave informed consent for the inclusion in
genetic studies on BPD. Written consent was given by the patients
for their information to be stored in the National Institute of
Heath database and used for research. No identifiable data were
used in this study. Only completely de-identified data had been
made available to the researchers involved in this study. The study
had been exempt from institutional review by the Institutional
Review Board at the University of California, Los Angeles, based
on the fact that only preexisting and completely de-identified data
were analyzed.
Sample
The BPD sample consisted of 1041 unrelated individuals from
the Foundation for the National Institutes of Health Genetic
Association Information Network (GAIN) Initiative (http://www.
genome.gov/19518664) [20]. Individuals were of European
descent according to self-reported heritage. The sample has been
used in several previously published studies [15,18,21]. Best-
estimate diagnosis procedures had been used to diagnose mood
disorder, as well as co-morbid conditions according to the
Diagnostic and Statistical Manual of Mental Disorder Version
III Revised (DSM-III-R) and DSM-IV diagnostic criteria [22].
Table 1. Demographic description of the bipolar disorder sample and controls.
Controls BPD Latent Class 1 Latent Class 2 Latent Class 3
N=1034 N=1000 N=258 N=249 N=493
100% 100% 26% 25% 49%
AGE (mean) 52 (SD=17.6) 42
# (SD=12.6) 41 (SD=12.6) 41 (SD=10.8) 44* (SD=13.8)
MAX 90 88 64 80 88
MIN 18 17 18 17 18
Female 502 (49%) 501 (50%) 160 (62%)* 96 (39%)* 240 (49%)*
Male 532 (51%) 499 (50%) 98 (38%) 153 (61%) 248 (51%)
BPD 0 (0%) 1000 (100%) 258 (100%) 249 (100%) 493 (100%)
BPD+SUB 0 336 (34%) 111 (43%) 200 (80%) 25 (5%)
BPD+OCD 0 82 (8%) 50 (19%) 24 (10%) 8 (2%)
BPD+PD 0 236 (24%) 97 (38%) 77 (31%) 62 (13%)
BPD+SP 0 161 (16%) 64 (25%) 57 (23%) 40 (8%)
BPD+ED 0 70 (7%) 37 (14%) 25 (10%) 8 (2%)
BPD+ADHD 0 97 (10%) 43 (17%) 50 (20%) 4 (1%)
BPD+ALCAB 0 134 (13%) 133 (52%) 1 (0.4%) 0 (0%)
BPD+ALCDEP 0 332 (33%) 0 (0%) 249 (100%) 83 (17%)
BPD+NIC 0 241 (24%) 90 (35%) 125 (50%) 26 (5%)
BPD+PSYCH 0 252 (25%) 105 (41%) 68 (27%) 79 (16%)
#Age was missing in 8 individuals, 5 males and 3 females, all of whom clustered into Latent Class 3.
*Significant at the 0.05 level in the Wald Chi-Square test when testing the equality of means across the latent classes.
SUBA, substance abuse; OCD, obsessive compulsive disorder; PD, panic disorder; SP, social and specific phobia; ED, eating disorder; ADHD, attention-deficit hyperactivity
disorder; ALCAB, alcohol abuse; ALCDEP, alcohol dependence; NIC, nicotine dependence; PSYCH, psychotic symptoms (presence of hallucinations and/or delusions).
doi:10.1371/journal.pone.0028477.t001
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morbid conditions was obtained based on the Diagnostic Interview
for Genetic Studies (DIGS) Version 3 and 4 (http://www.
nimhgenetics.org) [23], family information and medical records.
Multiple diagnoses per individual were allowed if diagnostic
criteria were fulfilled for each disorder independently. Information
about lifetime symptoms of hallucinations and/or delusions was
obtained through the K section of the DIGS. Based on these
information sources forty-one subjects did not meet full DSM-IV
criteria for BPD or schizoaffective disorder and therefore, they
were subsequently excluded from the analysis. The remaining
1000 individuals, all of whom were diagnosed with BPD type I,
were included in the latent class analysis and the genetic
association study. The cases consisted of 499 males and 501
females. The age at interview ranged from 17 to 88 years. The
mean age was 40.1 years, with a standard deviation (SD) of 12.6
years (Table 1). Age was missing in 8 individuals, 5 males and 3
females.
Co-morbid conditions were prevalent in the BPD patients
(Table 1, Figure 1). Conditions present in at least 5% of individuals
with BPD were used as indicators of the latent subclasses. Ten
variables fulfilled this criterion: substance abuse or dependence
(SUBA) (336 individuals), alcohol dependence (ALCDEP) (332
individuals), nicotine dependence (NIC) (241 individuals), panic
disorder (PD) (236 individuals), social phobia and specific phobia
(SP) (161 individuals). Alcohol abuse (ALCAB) (134 individuals),
attention deficit hyperactivity disorder (ADHD) (97 individuals),
obsessive compulsive disorder (OCD) (82 individuals), and eating
disorder (ED) (70 individuals) were only slightly more frequent than
in the general population [24]. Presence of psychotic symptoms,
such as hallucination and/or delusions (PSYCH) (252 individuals)
were also evaluated and included in the analysis, even though we
did not consider them as a co-morbid disorder, but rather a part of
the bipolar phenotype. Prior evidence suggested that these
symptoms might indicate a particular subtype of BPD [25].
The controls in the GAIN study had been ascertained
independently through an NIMH funded initiative. Originally, a
total of 4,586 subjects across the U.S. had been asked to complete
a psychiatric and medical questionnaire. Based on the response,
only individuals who did not fulfill diagnostic criteria for major
depression, psychosis or BPD were included as controls. Out of
this pool, one thousand and thirty-four control samples matched
for gender and ethnicity (532 males and 502 females) were selected
as controls in the GAIN sample. The age at interview ranged from
18 years to 90 years with a mean age of 52.5 years and a SD of
17.6 years. Since individual-level information on psychiatric
conditions and symptoms was not available for the controls, this
information could not be included in the latent class model. Our
analysis is therefore limited to the evaluation of co-morbid
conditions in the context of BPD only. The majority of cases
and controls were older than the average age of onset for BPD or
the co-morbid conditions, but since information on age was not
available on the individual level, uncertainties in some controls
could not be completely excluded. Since this study is a reanalysis of
publicly available data, these design issues were beyond our
control.
Latent class analysis
The LCA was performed in the statistical software program
Mplus [26]. The latent class membership was estimated by
maximum likelihood using the estimation maximization (EM)
algorithm [27]. We used 1000 random sets of starting values to
avoid local maxima in the log-likelihood. Missing data was
handled by including all available observations in line with the
assumption of ‘‘missing at random’’ (MAR) [28]. This assumption
allows for missingness to be a function of covariates in contrast to
Figure 1. Life-time prevalence of co-morbid conditions and psychotic symptoms in bipolar patients of the GAIN study compared to
lifetime prevalence in the National Comorbidity Survey Replication Study [51]. Co-morbid conditions and psychotic symptoms are
common in bipolar disorder. In the GAIN sample of 1000 bipolar patients, substance abuse/dependence was the most prevalent co-morbid condition,
followed by alcohol dependence. Nicotine dependence was present in about 25% of individuals. The prevalence of panic disorder was consistent
with other reports in the literature [23]. Attention deficit hyperactivity disorder, obsessive-compulsive disorder and eating disorder were generally
rare, present in less than 7% of individuals. As a comparison we used lifetime prevalence rates of psychiatric disorders from the National Comorbidity
Survey Replication Study (NCS-R). In this study the evaluation of ADHD was limited to a subsample of individuals age 44 and younger, which might
explain the high prevalence rate. Psychotic symptoms, nicotine dependence and eating disorders had not been evaluated in this study. SUBA,
substance abuse; ALCDEP, alcohol dependence; PSYCH, psychotic symptoms (presence of hallucinations and/or delusions); NIC, nicotine
dependence; PD, panic disorder; SP, social and specific phobia; ALCAB, alcohol abuse; ADHD, attention-deficit hyperactivity disorder; OCD, obsessive
compulsive disorder; ED, eating disorder.
doi:10.1371/journal.pone.0028477.g001
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variable with missing data was age at interview. The Bayesian
information criterion (BIC) was calculated for the different class
solutions, where the model with the smallest BIC was selected as
the best [29].
In this latent class framework, C denotes a latent variable, and
U stands for the binary, categorical or count observed indicator
variables. Let C denote a latent categorical variable with K classes,
Ci~(ci1,ci2,:::,ciK), where cik~1 if individual i belongs to class k
and zero otherwise. For U, conditional independence is assumed
given ci,
P(ui1,ui2,:::,uitjci)~P(ui1jci)P(ui2jci)P(uuitjci) ð1Þ
As a first step we conducted the latent class analysis without any
covariates in the model in order to understand the substantive
interpretation of the latent classes. Then we included sex and
age as auxiliary variables in the model. Conditional class specific
means were evaluated for each auxiliary variable based on the
estimated latent class model (option e in Mplus). We then tested
the equality of means across the latent classes using the Wald
Chi-Square test based on draws from the posterior probabi-
lities. The magnitude of the mean differences between the classes
was interpreted as an indicator for the strength of the predic-
tion that the auxiliary variable influenced the class membership
[30–32].
Genotyping and quality control
Genotyping was carried out by the Broad Institute Center for
Genotyping and Analysis using the Affymetrix Genome-Wide
Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA)
separately for cases and controls to facilitate sharing of controls
with the Genome-Wide Association Study of Schizophrenia
(dbGaP; Study Accession: phs000021.v2.p1). The identity of the
samples including gender identity had been checked at Rutgers
University by genotyping a 24-SNP panel on the Sequenom
iPLEX platform. A detailed description of the extensive quality
control of the data before public release can be found elsewhere
[20]. Even after those quality control measures, significant batch
effects due to non-randomization of cases and controls were
present in the publicly available data.
Therefore, in this analysis, we recalled the genotypes on the raw
signal intensity measurements of the data using the corrected robust
linear model with the maximum likelihood distance (CRLMM)
algorithm and the BEAGLECALL algorithm [33,34]. CRLMM
used the Oligo 1.6.0 package from Bioconductor 2.3. (http://www.
bioconductor.org /download/oldrelease/BioC2.3/). All samples
were run together in a single computational batch using default
parameters. Recently the BEAGLECALL methodology was intro-
duced to improve the accuracy of genotype calls through the use of
haplotype phase information and linkage disequilibrium (LD)
structure [35]. We used BEAGLECALL version 0.9.4, which
invokes the haplotype phasing methods of BEAGLE version 3.1.
[36].BEAGLECALLrequiresa matrixofgenotypeprobabilitiesfor
the 3 genotypes as well as normalized A and B allele intensities.
CRLMM calls were used as a starting point for BEAGLECALL –
all calls were made regardless of confidence, and the initial proba-
bilitiesfor eachcallwere set to one, with the othertwo genotype pro-
babilities set tozero. Autosomalallele intensities wereextracted from
the raw CEL files and quantile normalized [37] using Golden Helix
SNP & Variation Suite (SVS) software (http://www.goldenhelix.
com). Three iterations of BEAGLECALL were run with the re-
commended call thresholds of 0.8 for the first iteration, 0.96 for the
second and 0.97 for the third. We used the default BEAGLECALL
Hardy-Weinberg quality control threshold of 10
26. Genotype calls
with confidence less than 0.97 were set as missing. Our analysis was
limited to autosomal chromosomes only, since the BEAGLECALL
software currently does not support genotype calls for X and Y
chromosomal markers in male individuals. Starting with 868,157
autosomal calls from CRLMM, BEAGLECALL provided 796,664
high quality autosomal SNP calls. After eliminating SNPs with
minor allele frequency (MAF),0.001, the final dataset consisted of
728,331 autosomal SNPs. When association studies were performed
across all combined samples with the case/control status, the Q-Q
plots and Manhattan plots indicated little evidence of spurious
associations due to batch effects (File S1). A total of 1,000 cases and
1,034 controlshad genotypesand phenotypesthatmet quality control
standards and those were included in the genetic analysis using the
latent class membership probability as phenotype. We tested for
association under the dominant, additive and recessive model. Asso-
ciation analyses were performed with the SVS software from Golden
Helix. Correction for population stratification and outliers in the
genotype data was performed with principal component analysis
[38]. Q-Q plots were examined for each analysis (File S1) and cluster
plots were manually examined for all significant findings. Genome-
wide significant results were retested with 1,000 permutations. In
addition, we re-genotyped all genome-wide significant SNPs with the
TaqManH SNP Genotyping Assay from Applied Biosystems run on
the ABI 7900 Fast Real-Time PCR System (Life Technologies
Corporation, Carlsbad, CA, USA) according to the published proto-
col (http://www3.appliedbiosystems.com/cms/groups/mcb_support/
documents/generaldocuments/cms_042998.pdf). The genome brows-
er used for the bioinformatics analysis was the Ensemble database,
assembly GRCh37.p2, Feb 2009, Version 60.37e.
Results
Prevalence of co-morbid conditions
In the GAIN sample ascertained for genetic studies on bipolar
disorder, co-morbid conditions were prevalent. The frequency of
alcohol dependence, substance abuse and panic disorder in the
GAIN sample reflected the well-known and characteristic co-
morbidity in bipolar disorder that has emerged in recent studies in
the U.S., as well as worldwide. In this regard, this relatively small
sample was very similar to larger population samples of bipolar
disorder published in recent years [24,39]. However, the sample
differed from published data in the frequency of specific and social
phobias, ADHD and OCD, which were only slightly higher than
in the general population. The prevalence of alcohol abuse was
comparable to the prevalence in the National Comorbidity Survey
Replication Study (NCS-R) (). In order to evaluate possible
clustering of co-morbid conditions and unobserved subgroups of
individuals characterized by co-morbidity profiles, we performed a
latent class cluster analysis.
Latent class analysis
In the latent class analysis, subgroups of patients with significant
differences in co-morbidity profiles became apparent. A three-class
solution was selected as indicated by the Bayesian information
criterion (BIC) (Figure 2, Table 1). The entropy of the 3-class
solution was 0.694, indicating a fair separation of the latent classes.
Class 1 (26% of the sample) was BPD patients, who had a high
probability of endorsing substance abuse and psychotic symptoms.
Alcohol dependence was absent in this group (Table 2, Table 3).
Overall, 91% of individuals had received life-time diagnoses for
two or more co-morbid conditions in addition to BPD, 56% were
diagnosed with three or more additional co-morbid conditions,
and 24% carried four or more co-morbid diagnoses in addition to
Heterogeneity in Bipolar Disorder
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males. The mean age was 41 years with a standard deviation of
12.6. Class 2 (25% of the sample) was BPD with alcohol
dependence and substance abuse/dependence. In this group,
forty-seven percent had been diagnosed with four or more co-
morbid conditions and seventy-five percent of individuals carried
three or more diagnoses (Table 4). This class consisted of slightly
more males (61%) than females (39%). Regarding obsessive
compulsive disorder (OCD), panic disorder (PD), social phobia
(SP), eating disorder (ED), and attention-deficit hyperactivity
disorder (ADHD), Class 1 and Class 2 were not clearly differen-
tiated (Table 1, Table 2, Table 3). The probability of endorsing
psychotic symptoms (PSYCH) was higher in Latent Class 1 (41%)
compared to Latent Class 2 (27%). Individuals in Class 3 (49% of
the sample) were diagnosed with BPD, but their probability of
endorsing any co-morbid condition was very low. Six percent of
individuals were diagnosed with two co-morbid conditions; no
individual carried more than two co-morbid diagnoses in addition
to BPD. In 54% of individuals BPD was the only psychiatric
diagnosis (Table 4). This class consisted of equal numbers of males
and females and the mean age was the highest of all classes. In the
Wald test significant differences in age and sex were present in all
between-class comparisons, with the exception of the comparison
between Class 1 and Class 2 on age. Since the assumption of
heterogeneity in the sample with respect to co-morbidity was
supported by the data, we were interested in testing if bipolar
disorder with alcohol dependence might have different genetic risk
factors than bipolar disorder without alcohol dependence. Taking
heterogeneity with regard to co-morbid conditions into account
would facilitate the identification of common genomic variants
associated with specific sub-phenotypes.
Genome-wide association analysis
The genome-wide association analyses with the most likely latent
class membership as phenotype revealed three SNPs that reached or
approached the level of genome-wide significance, two SNPs were
associated with Latent Class 1 and one was associated with Latent
Class 2 (Figure 3, Figure 4, Table 5, Table 6). In patients with co-
morbidity in the absence of alcohol dependence (Latent Class 1)
highly significant associations under the recessive model were found
with SNP rs1039002 (p=1.7610
28, Bonf. P=0.017, Perm. P=
0.023) and SNP rs12563333 (p=5.9610
28, Bonf. P=0.04, Perm.
P=0.001). Rs1039002 is located on chromosome 6q27, 59 of the
processed transcript RP11-252P19-001 (OTTHUMG00000015988)
a n dc l o s et ot h eg e n ee n c o d i n gp h o s p h o d i e s t e r a s e1 0 A( PDE10A).
Rs12563333 is located within the transcribed gene sequence RP11-
410C4.4 (OTTHUMG00000037350) on chromosome 1q41 imme-
diately upstream of the gene encoding the MAP/microtubuleaffinity-
regulating kinase 1 (MARK1) (HGNC:6896). Homozygotes for the
minor allele of these SNPs were present only in Class 1 and absent in
all otherclassesorthe controls(Table6).Two SNPscameclose tothe
level of genome-wide significance. SNP rs9493867 on chromosome
6q23.2 within the gene encoding serine/threonine-protein kinase
(Sgk1) (HGNC:10810) was associated with Latent Class 1 under the
recessive model (p=1.0610
27). Homozygotes for SNP rs9493867
are absent in the HapMap sample. SNP rs13220542 located on
chromosome 6q15 was associated under the dominant model
(p=9.0610
28). This common variant is located 39 to the gene
Figure 2. Latent class solution of co-morbid conditions in bipolar disorder (BPD). Co-morbid conditions might indicate heterogeneity in
BPD. Latent class mixture modeling is a multivariate statistical approach to heterogeneity in data. The figure shows the co-morbidity profile of the
three latent classes of BPD patients. Latent Class 1 (red line and # symbol) consisted of BPD patients with substance abuse and/or psychosis and a
low probability of endorsing alcohol dependence. Class 2 (green line and D symbol) was BPD patients with a high probability of endorsing substance
abuse and alcohol dependence. The probability of endorsing nicotine dependence in this class was the highest of all latent classes. Regarding
obsessive compulsive disorder, panic disorder, social phobia, eating disorder, and attention-deficit hyperactivity disorder, Class 1 and Class 2 were not
clearly differentiated. Individuals in Class 3 (blue line and % symbol) were diagnosed with BPD, but their probability of endorsing any co-morbid
condition was very low. The x-axis indicates the co-morbid conditions included in the LCA. The y-axis represents the probability of endorsing co-
morbid conditions scaled from 0% to 100%. SUBA, substance abuse; OCD, obsessive compulsive disorder; PD, panic disorder; SP, social and specific
phobia; ED, eating disorder; ADHD, attention-deficit hyperactivity disorder; ALCAB, alcohol abuse; ALCDEP, alcohol dependence; NIC, nicotine
dependence; PSYCH, psychotic symptoms (presence of hallucinations and/or delusions).
doi:10.1371/journal.pone.0028477.g002
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(HGNC:6859). Both SNPs are located within gene regions.
BPD with high co-morbidity, substance abuse and alcohol
dependence (Latent Class 2) was associated with SNP rs2727943
on chromosome 3p26.3 under the recessive model (p=3.3610
28,
Bonf. P=0.02, Perm. P=0.03). SNP rs2727943 is a relatively
common SNP (homozygotes for the minor allele were found in 3%
of the HapMap samples) and it is not located in a gene region
(Table 5, Table 6). The odds ratio of being a bipolar case for
homozygote carriers of this SNP were 1.94; however, the odds
ratio for being in Latent Class 2 compared to Latent Class 1,
Latent Class 3 or controls was 4.9. No significant associations were
found with Latent Class 3 or when all BPD cases combined were
compared to the controls.
Discussion
In recent years, there has been increasing recognition of co-
morbid conditions in mental disorders. A deeper understanding of
this phenomenon and its risk factors could improve treatment and
prevention. Our results indicate heterogeneity in bipolar disorder
patients with regard to co-morbidity consistent with emerging
evidence from other studies. In this study we have explored possible
genetic risk factors that might shed some light on underlying patho-
mechanisms. Latent class analysis indicated the existence of
three distinct subgroups of patients characterized by co-morbidity
profiles, one group with predominantly substance abuse and/or
psychosis, one group in which alcohol dependence prevailed, and
one group with very low probability for any co-morbid conditions.
Addressing this heterogeneity led to the identification of several
highly significant associations with SNPs in genome-wide associa-
tion analyses. Our results suggest that phenotype heterogeneity in
BPD might indicate genetic heterogeneity. However, the interpre-
tation of our findings poses several problems. Since genome-wide
association analyses can, by design, only point to regions of the
genome associated with a disease phenotype, the actual functional
variants often remain elusive. Genome-wide association studies are
also underpowered to replicate association with rare variants.
Therefore, it is now commonly agreed upon that re-sequencing
approaches are necessary to follow-up on genome-wide association
studies and to identify the underlying causal variants.
The associations found in this study point to several interesting
genes and chromosomal regions that might justify re-sequencing
approaches in order to find the underlying functional variants. The
genomic variant rs1039002, which was associated with a subgroup
of bipolar patients with substance abuse and/or psychotic
symptoms, is located close to a transcribed genomic sequence with
unknown function. The product of the closest gene sequence with
known function is phosphodiesterase 10A (PDE10A), a protein
involved in the elimination of the intracellular signaling molecules
cAMP and cGMP. The highest expression levels of this gene are
found in heart, brain, kidney and testes. In the brain, expression is
particularly high in the medium spiny neurons of the striatum.
Inhibitors of this phosphodiesterase have shown therapeutic
potential for the treatment of psychotic symptoms in schizophrenia,
aswell asthetreatment ofParkinson’s disease,Huntington’sdisease,
Table 2. Probability of endorsing a co-morbid condition by
latent class.
Latent Class 1 Latent Class 2 Latent Class 3
SUBA 0.39 0.78 0.07
OCD 0.17 0.1 0.03
PD 0.37 0.31 0.12
SP 0.24 0.23 0.08
ED 0.12 0.10 0.03
ADHD 0.15 0.2 0.01
ALCAB 0.42 0 0.03
ALCDEP 0 1 0.18
NIC 0.30 0.47 0.08
PSYCH 0.40 0.29 0.17
All estimates were significant with two-tailed P-values,0.001 comparing the
probability of endorsing an item versus not endorsing an item. SUBA, substance
abuse; OCD, obsessive compulsive disorder; PD, panic disorder; SP, social and
specific phobia; ED, eating disorder; ADHD, attention-deficit hyperactivity
disorder; ALCAB, alcohol abuse; ALCDEP, alcohol dependence; NIC, nicotine
dependence; PSYCH, psychotic symptoms (presence of hallucinations and/or
delusions).
doi:10.1371/journal.pone.0028477.t002
Table 3. Comparison of latent class profiles using odds ratios.
LC1 compared to LC2 LC1 compared to LC3 LC2 compared to LC3
Estimate (S.E.) P value
* Estimate (S.E.) P value
* Estimate (S.E.) P value
*
SUBA 0.2 (0.1) 0.004 8.4 (3.9) 0.03 46.9 (19.9) 0.02
OCD 1.9 (0.6) 0.002 7.8 (6.8) 0.25 4.2 (3.4) 0.22
PD 1.3 (0.3) 0.000 4.4 (1.9) 0.02 3.5 (1.3) 0.006
SP 1.0 (0.3) 0.000 3.6 (1.7) 0.04 3.4 (1.4) 0.01
ED 1.1 (0.4) 0.001 5.1 (3.4) 0.14 4.5 (3.0) 0.14
ADHD 0.7 (0.2) 0.001 14.0 (13.5) 0.3 19.9 (18.7) 0.29
ALCAB 233 (340) 0.49 23.2 (25.0) 0.35 0.1 (0.2) 0.62
ALCDEP N/A N/A N/A N/A N/A N/A
NIC 0.5 (0.1) 0.000 4.9 (1.9) 0.01 10.2 (3.1) 0.001
PSYCH 1.6 (0.4) 0.000 3.4 (0.9) 0.000 2.1 (0.6) 0.000
*Two-tailed; LC, Latent Class; SUBA, substance abuse; OCD, obsessive compulsive disorder; PD, panic disorder; SP, social and specific phobia; ED, eating disorder; ADHD,
attention-deficit hyperactivity disorder; ALCAB, alcohol abuse; ALCDEP, alcohol dependence; NIC, nicotine dependence; PSYCH, psychotic symptoms (presence of
hallucinations and/or delusions).
doi:10.1371/journal.pone.0028477.t003
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are now being tested in clinical trials [40,41].
RP11-410C4.4 is the closest expressed sequence to the SNP
rs12563333, which is also associated with Latent Class 1 member-
ship. This gene is located immediately 59 to the serine/threonine-
protein kinase gene MARK1. MARK1 is highly expressed in brain
and testes, with highest levels of expression found in the hippo-
campus. MARK1 phosphorylates microtubule-associated proteins
and is involved in synaptic plasticity and dendritic trafficking [42].
Evidence for the involvement of this gene in autism has come from
gene expression studies in postmortem brains, as well as genome-
wide association studies [43]. Comparison of human MARK1 with
the mouse sequence showed significant differences and lack of
conservation. It has therefore been hypothesized that MARK1
could be involved in the development of higher cognitive functions
that separate humans from mice [44]. However, it remains to be
determined if rs12563333 is in linkage disequilibrium with any
functional variants in MARK1.
Table 4. Co-occurrence of co-morbid conditions.
Diagnoses per individual in addition to BPD Latent Class 1 Latent Class 2 Latent Class 3
Four or more disorders 24% 47% 0%
Three or more disorders 56% 75% 0%
Two or more disorders 91% 100% 6%
doi:10.1371/journal.pone.0028477.t004
Figure 3. Genome-wide association analysis for Latent Class 1 under the recessive model. The Manhattan plot demonstrates the results
of the genome-wide association analysis using the Latent Class 1 membership probability as phenotype. This subgroup of bipolar disorder patients
was characterized by co-morbidity with substance abuse in 43% of individuals. In this group, 24% of individuals had been diagnosed with four or
more co-morbid conditions in their lifetime. Alcohol abuse was prevalent in this patient group (52%), followed by substance abuse. Alcohol
dependence was absent. Psychotic symptoms were found in 41% of individuals; about half of those had also used illegal substances. The x-axis
depicts the position of the SNPs on the chromosomes with each chromosome shaded in a different color. The y-axis shows the 2log10 p-value of the
correlation trend test. The most significant finding was with the rare SNP rs1039002 on chromosome 6q27 (correlation trend test p=1.7610
28),
followed by rs12563333 on chromosome 1q41 (correlation trend test p=5.9610
28). Within the chromosomal region indicated by SNP rs1039002 is
the gene phosphodiesterase 10A. This gene has been implicated in the patho-physiology of psychosis in animal models.
doi:10.1371/journal.pone.0028477.g003
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located in genes that are involved in response to environmental
stresses, and therefore, might warrant further exploration. SNP
rs9493867 on chromosome 6q23.2 is located within the gene
serum/glucocorticoid regulated kinase 1 (Sgk1). This gene encodes
a serine/threonine-protein kinase that is involved in the activation
of potassium, sodium and chloride channels [45]. In rats it appears
to be involved in memory consolidation, spatial learning, and
cellular stress response through negative regulation of the SK1-
JNK1-MEKK1 pathway [46,47]. The second SNP is located in
the 39 region of the gene mitogen-activated protein kinase kinase
kinase 7 (MAP3K7) on chromosome 6q15. This serine/threonine
protein kinase is also involved in cell response to environmental
stresses in related pathways through activation of MAPK8/JNK
and the MAP2K4/MKK4 protein complex [48].
The most significant association with Latent Class 2 was within
a region that has been found to be deleted in individuals with
autistic features. SNP rs2727943 is located on chromosome 3p26.3
between the genes contactin-4 precursor (BIG-2) and the gene
encoding the neural adhesion molecule contactin 6 (CNTN6). The
protein products of these genes might play a role in the formation
of axon connections in the developing brain [49,50].
A limitation of our study is, foremost, the small sample size. Re-
sequencing of the most significant regions in a larger sample of
Figure 4. Genome-wide association analysis for Latent Class 2 under the recessive model. The Manhattan plot demonstrates the results
of the genome-wide association analysis using the Latent Class 2 membership probability as phenotype. This subgroup of bipolar disorder patients
was characterized by co-morbidity with alcohol dependence (100%) and substance abuse (80%). Forty-seven percent of individuals in this subgroup
carried lifetime diagnoses of four or more co-morbid conditions. The x-axis depicts the position of the SNPs on the chromosomes, each chromosome
shaded in a different color. The y-axis shows the 2log10 p-value of the correlation trend test. The most significant association with Latent Class 2
membership probability was with SNP rs2727943 on chromosome 3p26.3 (correlation/trend test p=3.0610
28). This common intergenic variant is
located between the genes contactin-4 precursor (BIG-2) and contactin 6 (CNTN6). Deletions in this chromosomal region have been previously
associated with autism spectrum disorders.
doi:10.1371/journal.pone.0028477.g004
Table 5. Results of genome-wide case control association
analyses using latent class membership as phenotype.
Class SNP Chr. Position Gene Corr. P Bonf. P
LC1 rs1039002 6q27 166155457 RP11-252P19.1 1.7610
28 0.01
rs12563333 1q41 218724857 MARK1 5.9610
28 0.04
LC2 rs2727943 3p26.3 1897973 intergenic 3.0610
28 0.02
This table gives the SNP phenotype associations that reached or approached
the genome-wide level of significance (after correction for multiple testing
using the Bonferroni method). The position of the SNPs on the chromosomes is
given in base pairs according to the Ensemble database, assembly GRCh37.p2,
Feb 2009, Version 60.37e. SNP, single nucleotide polymorphism; LC1, Latent
Class 1; LC2, Latent Class 2, Chr., chromosome; Corr P, p-value of the
correlation-trend test, Bonf. P, Bonferroni corrected p-value.
doi:10.1371/journal.pone.0028477.t005
Heterogeneity in Bipolar Disorder
PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28477bipolar patients would be desirable in order to evaluate all variants
in the identified genomic regions and to determine their functional
consequences. The high genotype quality of the re-called and re-
genotyped significant SNPs, the fact that the identified rare variants
were present only in cases and not in controls and strong evidence
for the therapeutic potential of PDE10A inhibitors might justify
further follow-up studies. Our analysis indicates three major points.
1. Rare variants might be important pathogenic factors in BPD.
Rare variants ingene regions werethe most significantsignals inour
analysis, and these variants were exclusively present in cases and not
in controls. In our small sample and without replication it is difficult
to claim certainty about the disease association; however, cumula-
tive evidence for the implication of the identified genomic regions
could justify further investigation. 2. Since the associated variants
were very rare, a genome-wide association design might not be the
most appropriate approach for replication. Future studies could
focus on re-sequencing of the chromosomal regions in a sample of
BPD patients and controls in order to identify all rare and possibly
coding variants in the region that might play a role in BPD
pathophysiology. The fact that all of our associations were found in
or near genes that have been implicated in psychiatric disorders and
even in psychosis underlines the importance of these significant
associations. 3. Taking the heterogeneity of the phenotype into
account when performing disease association studies might increase
the power of detecting significant associations.
Insummary, ourpaperdescribes a novel multivariate approach to
the phenotype of BPD. We identified rare variants in regions of
interestthatmightwarrantfurtherstudies.However,wewereunable
to find common variants with functional consequences associated
with BPD. Focused or genome-wide re-sequencing might be
important for the identification of genetic risk factors in bipolar
disorder.
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